When was Elevation Oncology founded?

Elevation Oncology was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Elevation Oncology located?

Elevation Oncology is headquartered in New York City, United States.

How many employees does Elevation Oncology have?

As of Jun 30, 2026, the latest employee count at Elevation Oncology is 5.

Is Elevation Oncology a funded company?

Elevation Oncology is a funded company, having raised a total of $97.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 21, 2020.

When was the latest funding round of Elevation Oncology?

Elevation Oncology's latest funding was a $***** Series B round on Nov 17, 2020, with participation from 13 investors. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.58B in funding in 2026 to date.

Where does Elevation Oncology rank among its competitors?

Elevation Oncology ranks 844th amongst 3315 active competitors, of which 1130 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Elevation Oncology?

Elevation Oncology's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Elevation Oncology - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of precision medicine for the treatment of cancer. It has developed drugs to inhibit the specific alterations that can identify drivers of cancer. Its lead drug candidate, Seribantumab inhibits tumor growth driven by NRG1 gene fusions and EO-3021 is an ADC containing monomethyl auristatin E (MMAE) payload which targets Claudin18.2 protien for the treatment of gastrointestinal cancers.

Website: elevationoncology.com
Email ID: *****@elevationoncology.com
Phone Number: +1 **********

Key Metrics

Founded Year

2019

Location

New York City, United States

Stage

Public

Total Funding

$97.5M in 2 rounds

Latest Funding Round

Series B, Nov 17, 2020, $*****

Investors

Aisling Capital & 14 more

Ranked

844^th among 3315 active competitors

Employee Count

5 as on Jun 30, 2026

Similar Companies

BeiGene & 633 more

Exit Details

Public

View Elevation Oncology's full profile

Elevation Oncology is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ELEVATION ONCOLOGY, INC. CIN: 1783032 , United States, Active	Apr 28, 2019	-	29 (As on Dec 31, 2023)	-
ELEVATION ONCOLOGY, INC CIN: 84-1771427 , United States, Active	Apr 28, 2019	-	35 (As on Dec 31, 2021)	-

Elevation Oncology got listed on Jun 25, 2021.

Click here to take a look at Elevation Oncology's IPO in detail

Elevation Oncology has raised a total funding of $97.5M over 2 rounds. Its first funding round was on Jul 21, 2020. Its latest funding round was a Series B round on Nov 17, 2020 for $*****. 13 investors participated in its latest round. Elevation Oncology has 14 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Elevation Oncology:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 17, 2020	3522582	Series B	8301918	4278239	9068970	9515036
Jul 21, 2020	1352306	Series A	6042225	9007273	Aisling Capital	Vertex Ventures HC & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Elevation Oncology's funding rounds and investors

The founders of Elevation Oncology is Shawn Leland.

Here are the details of Elevation Oncology's key team members:

Shawn Leland: Founder of Elevation Oncology. They are also an angel investor in 1 startup.

View details of Elevation Oncology's Founder profiles and Board Members

Elevation Oncology's employee count trend

Elevation Oncology has 5 employees as of Jun 26. Here is Elevation Oncology's employee count trend over the years:

Employee count trend for Elevation Oncology

Uncover Elevation Oncology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Elevation Oncology include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Elevation Oncology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
844th	Elevation Oncology 2019, New York City (United States), Public	Developer of precision medicine for the treatment of cancer	$97.5M	BVF Partners, Boxer Capital & 13 others	44/100